Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver
- 30 January 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 109 (9), 3510-3515
- https://doi.org/10.1073/pnas.1112209109
Abstract
A 30-d course of oral administration of a semipurified extract of the root of Withania somnifera consisting predominantly of withanolides and withanosides reversed behavioral deficits, plaque pathology, accumulation of β-amyloid peptides (Aβ) and oligomers in the brains of middle-aged and old APP/PS1 Alzheimer's disease transgenic mice. It was similarly effective in reversing behavioral deficits and plaque load in APPSwInd mice (line J20). The temporal sequence involved an increase in plasma Aβ and a decrease in brain Aβ monomer after 7 d, indicating increased transport of Aβ from the brain to the periphery. Enhanced expression of low-density lipoprotein receptor-related protein (LRP) in brain microvessels and the Aβ-degrading protease neprilysin (NEP) occurred 14–21 d after a substantial decrease in brain Aβ levels. However, significant increase in liver LRP and NEP occurred much earlier, at 7 d, and were accompanied by a rise in plasma sLRP, a peripheral sink for brain Aβ. In WT mice, the extract induced liver, but not brain, LRP and NEP and decreased plasma and brain Aβ, indicating that increase in liver LRP and sLRP occurring independent of Aβ concentration could result in clearance of Aβ. Selective down-regulation of liver LRP, but not NEP, abrogated the therapeutic effects of the extract. The remarkable therapeutic effect of W. somnifera mediated through up-regulation of liver LRP indicates that targeting the periphery offers a unique mechanism for Aβ clearance and reverses the behavioral deficits and pathology seen in Alzheimer's disease models.Keywords
This publication has 19 references indexed in Scilit:
- Alzheimer's disease: strategies for disease modificationNature Reviews Drug Discovery, 2010
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Withania somnifera: An Indian ginsengProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2007
- Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the LiverPharmaceutical Research, 2006
- Withanoside IV and its active metabolite, sominone, attenuate Aβ(25–35)‐induced neurodegenerationEuropean Journal of Neuroscience, 2006
- The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) SubstratePublished by Elsevier BV ,2005
- Neuritic regeneration and synaptic reconstruction induced by withanolide ABritish Journal of Pharmacology, 2005
- Clearance of Alzheimer's Aβ Peptide: The Many Roads to PerditionNeuron, 2004
- LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ IsoformsNeuron, 2004
- Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrierJCI Insight, 2000